Reviewing Voyager Therapeutics (NASDAQ:VYGR) & Novavax (NVAX)

Voyager Therapeutics (NASDAQ: VYGR) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Institutional and Insider Ownership

40.7% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 45.2% of Novavax shares are owned by institutional investors. 6.0% of Voyager Therapeutics shares are owned by insiders. Comparatively, 4.0% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Voyager Therapeutics and Novavax, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics 0 1 7 0 2.88
Novavax 0 5 2 0 2.29

Voyager Therapeutics currently has a consensus price target of $24.83, suggesting a potential upside of 41.90%. Novavax has a consensus price target of $3.35, suggesting a potential upside of 188.79%. Given Novavax’s higher possible upside, analysts clearly believe Novavax is more favorable than Voyager Therapeutics.

Volatility and Risk

Voyager Therapeutics has a beta of 3.65, indicating that its share price is 265% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.

Earnings and Valuation

This table compares Voyager Therapeutics and Novavax’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Voyager Therapeutics $8.31 million 56.65 -$59.32 million ($2.30) -7.61
Novavax $21.04 million 15.98 -$186.64 million ($0.77) -1.51

Voyager Therapeutics has higher revenue, but lower earnings than Novavax. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.


This table compares Voyager Therapeutics and Novavax’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Voyager Therapeutics -712.22% -46.15% -32.66%
Novavax -1,006.00% -787.38% -53.89%


Voyager Therapeutics beats Novavax on 9 of the 13 factors compared between the two stocks.

About Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain. The Company’s clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson’s disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

About Novavax

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply